Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SpareBank 1 Markets in connection with its partnership with Swedbank
Mandate

Vinge advises SpareBank 1 Markets in connection with its partnership with Swedbank

March 04, 2025 M&A Financial Regulatory

The partnership between SpareBank 1 Markets and Swedbank aims to create a leading Nordic investment bank. As part of the transaction, SpareBank 1 Markets will receive Swedbank’s Corporate Finance and DCM High-Yield business in Sweden and establish a branch in Stockholm through which the business operations will be conducted.

Pursuant to the partnership, Swedbank will become part-owner of SpareBank 1 Markets with a 20% stake thereby strengthening the position of both banks in the Nordic market and creating new opportunities for expansion in investment banking.

The transaction is subject to regulatory approvals and customary closing conditions.

Vinge’s team primarily consists of Samra Tesser, Nils Unckel, Anton Sjökvist and Gustav Wahlberg.

Related

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025